TickerHumSide-by-side comparison
AbbVie vs Pfizer
As of Nov 11, 2026, P/E is 50.4x for AbbVie vs 41.8x for Pfizer; P/S is 7.8x for AbbVie vs 2.6x for Pfizer; revenue growth is 10.7% for AbbVie vs 1.3% for Pfizer; net margin is 15.7% for AbbVie vs 6.3% for Pfizer.
What stands out
- AbbVie scores higher on TickerHum's ratings: 62/100 vs 51/100 for Pfizer.
Key metrics
| Metric | ABBV | PFE |
|---|---|---|
| Price | $292.77 | $29.28 |
| Market cap | $517.5B | $166.86B |
| P/E | 50.4x (#2) | 41.8x (#1) |
| P/S | 7.8x (#2) | 2.6x (#1) |
| Revenue growth | 10.7% (#1) | 1.3% (#2) |
| Operating margin | 32.2% (#1) | — |
| Net margin | 15.7% (#1) | 6.3% (#2) |
| Debt / equity | — | 0.67 (#1) |
| 1-year return | +25.5% (#1) | +13.2% (#2) |
| Research score | 62/100 (#1) | 51/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- AbbVie Inc. (ABBV) — Drug Manufacturers—General
- Pfizer Inc. (PFE) — Drug Manufacturers—General